Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis
D Aradi, A Komócsi, A Vorobcsuk, O Rideg… - American heart …, 2010 - Elsevier
BACKGROUND: A growing number of observational studies suggest that high on-
clopidogrel platelet reactivity (HPR) is associated with recurrent thrombotic events after …
clopidogrel platelet reactivity (HPR) is associated with recurrent thrombotic events after …
High on-treatment platelet reactivity–definition and measurement
M Cattaneo - Thrombosis and haemostasis, 2013 - thieme-connect.com
In the last decade, several studies revealed inter-patient response variability to antiplatelet
agents: patients who display negligible or no responses to these drugs are considered poor …
agents: patients who display negligible or no responses to these drugs are considered poor …
Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention
O Rideg, A Komócsi, T Magyarlaki… - …, 2011 - Taylor & Francis
Aim: To determine the effect of various SNPs on post-clopidogrel platelet reactivity and
clinical outcome. Materials & methods: Cytochrome 2C19 (CYP2C19) loss-of-function (LOF; …
clinical outcome. Materials & methods: Cytochrome 2C19 (CYP2C19) loss-of-function (LOF; …
Effects of VerifyNow P2Y12 test and CYP2C19* 2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis
Y Yamaguchi, T Abe, Y Sato, Y Matsubara, T Moriki… - Platelets, 2013 - Taylor & Francis
The VerifyNow P2Y12 test is a whole-blood, light transmission-based optical detection
assay that measures adenosine diphosphate-induced platelet aggregation in a cartridge …
assay that measures adenosine diphosphate-induced platelet aggregation in a cartridge …
Justification of 150 mg clopidogrel in patients with high on‐clopidogrel platelet reactivity
D Aradi, O Rideg, A Vorobcsuk… - European journal of …, 2012 - Wiley Online Library
Eur J Clin Invest 2012; 42 (4): 384–392 Abstract Background The GRAVITAS trial showed
that 150 mg clopidogrel did not improve outcome in patients with high on‐clopidogrel …
that 150 mg clopidogrel did not improve outcome in patients with high on‐clopidogrel …
[HTML][HTML] The prognostic utility of tests of platelet function for the detection of'aspirin resistance'in patients with established cardiovascular or cerebrovascular disease: a …
J Dretzke, RD Riley, M Lordkipanidzé… - Health Technology …, 2015 - europepmc.org
Background The use of aspirin is well established for secondary prevention of
cardiovascular disease. However, a proportion of patients suffer repeat cardiovascular …
cardiovascular disease. However, a proportion of patients suffer repeat cardiovascular …
Resistance to clopidogrel: prevalence and associate variables
FB Silva, GLG Almeida Junior, A Neno… - Arquivos Brasileiros …, 2012 - SciELO Brasil
Background: The dual antiplatelet therapy with acetylsalicylic acid (ASA) and clopidogrel is
the cornerstone of treatment for patients undergoing angioplasty with coronary stent …
the cornerstone of treatment for patients undergoing angioplasty with coronary stent …
Outcomes of patients receiving clopidogrel prior to cardiac surgery
A Vorobcsuk, D Aradi, K Farkasfalvi, IG Horváth… - International journal of …, 2012 - Elsevier
BACKGROUND: Clinical impact of the concomitant clopidogrel therapy on clinical outcomes
in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically …
in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically …
Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition
D Aradi, T Magyarlaki, M Tőkés-Füzesi, O Rideg… - Platelets, 2010 - Taylor & Francis
No consensus exists regarding the optimal estimate of light transmission aggregometry
(LTA) to reflect P2Y12 ADP receptor inhibition in patients receiving thienopyridine therapy …
(LTA) to reflect P2Y12 ADP receptor inhibition in patients receiving thienopyridine therapy …
Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity
D Aradi, A Vorobcsuk, Z Lenkey, IG Horváth, A Komócsi - Platelets, 2010 - Taylor & Francis
Raising the maintenance dose of clopidogrel to 150 mg enhances platelet inhibition (PI) in
patients with elevated platelet reactivity (EPR); however, large differences were observed …
patients with elevated platelet reactivity (EPR); however, large differences were observed …